Related by context. All words. (Click for frequent words.) 76 prostate cancer CRPC 73 hormone refractory prostate cancer 72 castrate resistant prostate cancer 72 HER2 positive metastatic breast 72 metastatic renal cell carcinoma 72 leukemia AML 71 refractory multiple myeloma 71 metastatic castration resistant 71 metastatic hormone refractory 70 mRCC 69 leukemia CLL 69 metastatic RCC 69 recurrent NSCLC 69 cell lymphoma CTCL 69 HRPC 69 stage IIIB 68 androgen independent 68 metastatic prostate cancer 68 NSCLC 68 Bezielle 68 phase IIb clinical 68 castration resistant 68 Genasense ® 68 HGS ETR1 67 unresectable stage 67 pancreatic adenocarcinoma 67 prostate cancer HRPC 67 metastatic CRPC 67 alvespimycin 67 K ras mutations 67 cediranib 67 heavily pretreated 67 BRAF mutation 67 mCRC patients 67 prostate cancer AIPC 67 IV metastatic melanoma 67 relapsed refractory multiple myeloma 66 IMA# 66 dasatinib Sprycel ® 66 lymphoma CTCL 66 CYT# potent vascular disrupting 66 hormone refractory 66 trastuzumab Herceptin ® 66 TACI Ig 66 IV NSCLC 66 docetaxel chemotherapy 66 recurrent glioblastoma 66 HGS ETR2 66 erlotinib Tarceva ® 66 gefitinib Iressa 66 Proxinium TM 66 imatinib Gleevec 66 recurrent GBM 66 elotuzumab 66 INCB# [001] 66 prostate cancer CaP 66 T#I mutation 66 luteinizing hormone releasing 66 medullary thyroid cancer 66 leukemia ALL 65 B CLL 65 relapsed multiple myeloma 65 metastatic colorectal cancer 65 antiangiogenic therapy 65 Bortezomib 65 recurrent glioblastoma multiforme 65 elacytarabine 65 metastatic HRPC 65 CR# vcMMAE 65 targeting CD# 65 CTAP# Capsules 65 MAGE A3 ASCI 65 metastatic castrate resistant 65 gastrointestinal stromal tumors GIST 65 gastrointestinal stromal tumor GIST 65 refractory AML 65 IRX 2 65 humanized anti 65 alkylating agent 65 BRIM2 65 axitinib 65 prostate carcinoma 65 pan HDAC inhibitor 65 relapsing multiple sclerosis 65 antibody MAb 65 Ceflatonin 65 metastatic malignant melanoma 65 T#I [002] 65 HER2 positive breast cancer 65 anti angiogenic therapy 65 Xanafide 65 hepatocellular carcinoma HCC 65 advanced NSCLC 65 imatinib therapy 65 Pralatrexate 65 EGFR inhibitors 65 relapsing MS 65 HER2 positive 65 ALK inhibitor 65 imatinib resistant 65 superficial bladder cancer 65 EGFR mutations 65 Gleevec resistant 65 refractory gout 64 LHRH receptor positive 64 decitabine 64 oral ridaforolimus 64 pancreatic neuroendocrine tumors 64 castrate resistant 64 acute myelogenous leukemia AML 64 chronic lymphocytic leukemia CLL 64 refractory CLL 64 fallopian tube carcinoma 64 Fibrillex TM 64 BAY #-# 64 registrational trial 64 gastrointestinal stromal tumors 64 neoadjuvant chemotherapy 64 medically inoperable 64 depsipeptide 64 imatinib Gleevec ® 64 sipuleucel T 64 Traficet EN 64 ganetespib 64 dasatinib Sprycel 64 tanespimycin 64 PROSTVAC VF 64 selective modulator 64 CBLC# 64 IV melanoma 64 epithelial tumors 64 cetuximab Erbitux ® 64 colorectal liver metastases 64 dasatinib 64 bevacizumab Avastin ® 64 oral prodrug 64 Aflibercept 64 demonstrated antitumor activity 64 tumors GIST 64 pertuzumab 64 chronic myeloid leukemia CML 64 metastatic gastric 64 cutaneous T cell 64 OncoVEX GM CSF 64 relapsed ovarian cancer 64 HBeAg negative 64 radiation sensitizer 64 metastatic colorectal 64 CCX# 64 AP# [003] 64 forodesine 64 HER2 negative 64 hepatocellular carcinoma 64 orally administered inhibitor 63 prostate cancer mCRPC 63 Vicinium TM 63 CD3 monoclonal antibody 63 relapsing remitting multiple sclerosis 63 Trastuzumab 63 unresectable tumors 63 cilengitide 63 Aurora kinase 63 PXD# 63 CD# antibody [001] 63 virus HCV protease inhibitor 63 PEG SN# 63 lintuzumab 63 brain metastases 63 Hepatocellular Carcinoma HCC 63 cancer mCRC 63 panobinostat 63 ovarian carcinoma 63 KRAS mutation 63 MPS IVA 63 Cutaneous T 63 interferon alfa 63 situ CIS 63 vemurafenib 63 CDK inhibitor 63 HBeAg positive 63 CIMZIA ™ 63 ALN TTR 63 AGILECT R 63 bone metastases 63 Voreloxin 63 FLT3 63 biliary tract cancer 63 Enzastaurin 63 Cloretazine ® 63 cell malignancies 63 huC# DM4 63 PSMA ADC 63 HCV SPRINT 63 vandetanib 63 APOPTONE 63 Dapagliflozin 63 JAK inhibitors 63 metastatic melanoma 63 Annamycin 63 CD# monoclonal antibody 63 temsirolimus 63 bone metastasis 63 EOquin 63 Epratuzumab 63 Neovascular AMD 63 YONDELIS 63 relapsed leukemia 63 Quinamed 63 adecatumumab 63 CYC# 63 PROVENGE sipuleucel T 63 EGFR mutation 63 alkylating agents 63 CaP 63 dexpramipexole 63 carcinoid syndrome 63 familial amyloidotic polyneuropathy FAP 63 ELACYT 63 relapsed SCLC 63 interferon therapy 63 goserelin 63 Myelodysplastic Syndrome MDS 63 liver metastases 63 chlorambucil 63 fosbretabulin 63 receptor tyrosine kinase inhibitor 63 sorafenib Nexavar 63 irreversible inhibitor 63 mapatumumab 63 refractory cutaneous T 63 CA4P 63 chronic myelogenous leukemia CML 63 stage IIIb IV 63 trabectedin 63 nucleoside analog 63 gefitinib 63 relapsed MM 63 trastuzumab Herceptin R 63 AA amyloidosis 62 PANVAC VF 62 Phase Ib study 62 PEGylated Fab fragment 62 Curaxin CBLC# 62 pegylated liposomal doxorubicin 62 resistant ovarian cancer 62 myeloproliferative diseases 62 idarubicin 62 IMC A# 62 Tyrima 62 hematological cancers 62 multiple myeloma MM 62 FOLFOX6 62 IL# PE#QQR 62 dirucotide 62 romidepsin 62 hormone receptor positive 62 metastatic CRC 62 proteasome inhibitor 62 Azedra 62 anticancer compound 62 galiximab 62 cetuximab Erbitux R 62 Degarelix 62 myelofibrosis polycythemia vera 62 obatoclax 62 mCRC 62 vidofludimus 62 olaparib 62 HCV infected 62 Neuvenge 62 nonsmall cell lung cancer 62 refractory CTCL 62 Abiraterone acetate 62 ribavirin RBV 62 Amrubicin 62 Plicera 62 pancreatic NET 62 blinatumomab 62 ZOLINZA 62 refractory NSCLC 62 Cell Lymphoma 62 BRIM3 62 follicular NHL 62 cutaneous T 62 AEG# 62 SAR# [004] 62 zanolimumab 62 unresectable 62 evaluating tivozanib 62 resectable 62 Cloretazine 62 epithelial ovarian 62 thalidomide Thalomid 62 EOquin TM 62 KRAS wild 62 non alcoholic steatohepatitis 62 HuMax EGFr 62 Virulizin ® 62 SCCHN 62 glufosfamide 62 dacarbazine 62 estramustine 62 recurrent ovarian cancer 62 BRAF V#E mutation 62 Irinotecan 62 Hodgkin lymphoma NHL 62 non metastatic osteosarcoma 62 INCB# [002] 62 LY# [003] 62 refractory chronic lymphocytic 62 mGluR5 NAM 62 basal cell carcinoma BCC 62 asymptomatic metastatic 62 trastuzumab DM1 T DM1 62 PKC# 62 neoadjuvant therapy 62 ZACTIMA 62 pharmacokinetic interactions 62 symptomatic BPH 62 bladder carcinoma 62 Factor VIIa 62 systemic anaplastic large 62 differentiated thyroid 62 taxane chemotherapy 62 PROSTVAC TM 62 docetaxel Taxotere ® 62 hormone deprivation 62 Omacetaxine 62 myeloproliferative disorders 62 MDV# 62 RG# [001] 62 phase IIb trial 62 PREZISTA r 62 PCa 62 nucleoside analogue 62 metastatic malignant 62 lymphoid malignancies 62 HER2 overexpression 62 breast carcinoma 62 malignant pleural mesothelioma 62 platinum refractory 62 PRTX 62 entinostat 62 PNP inhibitor 62 Acute Myeloid Leukemia AML 62 Afatinib 62 metastatic breast cancer 62 GW# [003] 62 solid tumors 62 trastuzumab DM1 62 IAP inhibitors 62 glioblastoma multiforme GBM 62 enzastaurin 62 Apoptone 62 clinically localized prostate 62 refractory acute myeloid 62 renal cell carcinoma 62 eosinophilic asthma 62 mTOR inhibitor 62 liposomal formulation 62 Genz # 62 metaglidasen 62 AVASTIN 62 EGFr 62 sorafenib tablets 62 taxane resistant 62 metastatic colorectal carcinoma 62 refractory metastatic 62 XmAb# 62 HuMax CD4 62 Neoadjuvant 62 carcinoid 62 JAK2 inhibitor 62 cabazitaxel 62 TELCYTA 61 Aurexis 61 ATL# [001] 61 operable breast cancer 61 SPRYCEL ® 61 dacarbazine DTIC 61 DAPT 61 vismodegib 61 microtubule targeting 61 fulvestrant 61 GAMMAGARD 61 EGFR tyrosine kinase inhibitor 61 ONCONASE 61 nab paclitaxel 61 posaconazole 61 anthracyclines taxanes 61 EGFR tyrosine kinase inhibitors 61 metastatic neuroendocrine tumors 61 novel VDA molecule 61 EGFR TKI 61 FOLFIRI 61 trastuzumab Herceptin 61 PEG Interferon lambda 61 Telintra 61 Hodgkin lymphoma HL 61 histone deacetylase HDAC inhibitor 61 EDEMA3 61 advanced metastatic prostate 61 Aplidin 61 curative resection 61 Romidepsin 61 HuLuc# 61 Motesanib 61 CRPC 61 IMGN# 61 Gemzar ® 61 diabetic neuropathic pain 61 pheochromocytoma 61 XL# XL# XL# 61 FOLFOX4 61 histologies 61 pancreatic carcinoma 61 GPNMB 61 docetaxel prednisone 61 Dasatinib 61 lupus nephritis 61 BiTE antibody 61 EGFRvIII 61 hypomethylating agents 61 paclitaxel Taxol R 61 docetaxel Taxotere R 61 neuroendocrine tumors 61 tyrosine kinase inhibitors 61 Ophena TM 61 Tamibarotene 61 gemcitabine Gemzar 61 Daclizumab 61 visilizumab 61 idiopathic pulmonary fibrosis IPF 61 erlotinib Tarceva 61 investigational humanized monoclonal antibody 61 Ofatumumab 61 viral kinetics 61 pomalidomide 61 colorectal carcinoma 61 pralatrexate 61 mertansine 61 mCRPC 61 PEGylated interferon beta 1a 61 inhibitor RG# 61 metastatic disease 61 talactoferrin 61 recurrent glioma 61 thymalfasin 61 neoadjuvant 61 ALN PCS 61 sunitinib Sutent ® 61 ADPKD 61 amrubicin 61 urothelial bladder cancer 61 metastatic GIST 61 metastatic bladder 61 MetMAb 61 abiraterone acetate 61 Targretin 61 LY# [002] 61 TRO# 61 Metastatic breast cancer 61 CoFactor 61 Akt inhibitor 61 JAK1 61 phase IIa clinical 61 PDX pralatrexate 61 prostate cancer PCa 61 riociguat 61 acute GvHD 61 distant metastases 61 null responder 61 VEGFR2 inhibitor 61 Camptosar ® irinotecan 61 chronic HCV 61 taxane therapy 61 standard chemotherapy regimen 61 TNF antagonist 61 interferon IFN 61 CEQ# 61 LymphoStat B 61 RRMS patients 61 assessing T DM1 61 HQK 61 MyVax R 61 Triapine 61 Erlotinib 61 Tanespimycin 61 ACTEMRA TM 61 systemically administered 61 virus HCV infection 61 Glufosfamide 61 relapsed ALL 61 OXi# 61 Phenoptin 61 metastatic renal cell 61 hematologic malignancies 61 K ras 61 ZYBRESTAT 61 T2DM 61 Doxil ® 61 plus prednisone 61 hepatic metastases 61 Pertuzumab 61 multi kinase inhibitor 61 BRCA deficient 61 Elotuzumab 61 FOLOTYN 61 Mipomersen 61 AMN# [001] 61 myelodysplastic syndromes MDS 61 budesonide foam 61 PRT# 61 IMC #B 61 HBeAg positive patients 61 Intravenous CP 61 polycythemia vera PV 61 androgen deprivation 61 Velcade bortezomib 61 custirsen 61 bosentan 61 lumiliximab 61 rindopepimut 61 HCV protease inhibitor 61 MYDICAR ® 61 Onalta ™ 61 bevacizumab Avastin 61 hormone LHRH antagonist 61 PI3K/Akt pathway inhibitor 60 gastric adenocarcinoma 60 ocrelizumab 60 synthetic retinoid 60 vascular disrupting agent 60 HCV RESPOND 2 60 chemoradiotherapy 60 drug conjugate 60 CANCIDAS 60 IgG1 monoclonal antibody 60 HCV protease 60 hepatocellular cancer 60 CIMZIA TM 60 refractory colorectal cancer 60 anti leukemic 60 ribavirin Copegus ® 60 vinorelbine 60 WT1 60 Ocrelizumab 60 hepatic fibrosis 60 noninfectious uveitis 60 sorafenib Nexavar ® 60 targeted radiotherapeutic 60 Alemtuzumab 60 paclitaxel Taxol ® 60 Personalized Immunotherapy 60 nonmetastatic 60 PSN# [002] 60 Clusterin 60 Panzem R NCD 60 cytotoxic therapy 60 nilotinib Tasigna ® 60 EOquin TM phase 60 Nexavar sorafenib 60 ongoing Phase 1b 60 sodium glucose cotransporter 60 IMPACT IMmunotherapy 60 MGCD# [001] 60 efalizumab 60 Sipuleucel T 60 beta 1a 60 pediatric malignancies 60 follicular lymphoma 60 fluoropyrimidine 60 metastatic lung cancer 60 ALN VSP 60 ON #.Na 60 GvHD 60 activating mutations 60 fallopian tube cancers 60 perifosine 60 non squamous NSCLC 60 histologically confirmed 60 Phase 2b study 60 metastatic cancer 60 bleomycin 60 hormone LHRH 60 PD LID 60 Hsp# Inhibitor 60 aflibercept VEGF Trap 60 HER2/neu 60 SHPT 60 IgG1 antibody 60 phase IIb study 60 KRAS mutant tumors 60 pediatric acute lymphoblastic 60 Pemetrexed 60 oblimersen 60 Fludara ® 60 lintuzumab SGN 60 MGd 60 EpCAM 60 sunitinib 60 IGF 1R 60 nilotinib 60 Pradefovir 60 heavily pretreated patients 60 antiangiogenic 60 adriamycin 60 Amplimexon 60 OvaRex ® MAb 60 Troxatyl 60 TORISEL 60 ancrod 60 BRAF V# mutation 60 OMNARIS HFA 60 terlipressin 60 seliciclib 60 angiogenesis inhibitor 60 estrogen receptor ER 60 Phase IIa trial 60 XELOX 60 Zolinza 60 sapacitabine 60 Phase 2a trial 60 adjuvant therapy 60 HBeAg negative chronic hepatitis 60 preoperative chemotherapy 60 interferon gamma 1b 60 bortezomib 60 tarenflurbil 60 untreated metastatic melanoma 60 STRIDE PD 60 IGF IR 60 compound AEZS 60 Squalamine 60 Blinatumomab 60 prostate adenocarcinoma 60 primary hypercholesterolemia 60 OMP #R# 60 darapladib 60 PROVENGE 60 RNAi therapeutic targeting 60 Amigal 60 Phase #/#a trial 60 Advanced Renal Cell 60 FOLOTYN ® 60 ELND# 60 baminercept 60 PLX# 60 ponatinib 60 recurrent metastatic 60 locoregional 60 bispecific antibody 60 adjuvant radiotherapy 60 NSCLC tumors 60 octreotide 60 p# biomarker 60 mediated apoptosis 60 cell lymphoma ALCL 60 Solazed ™ 60 cariprazine 60 Cotara 60 refractory indolent non 60 TTR gene 60 Ozarelix 60 Phase 2a clinical 60 HDACi 60 small molecule Hedgehog 60 FOLFOX regimen 60 oral nucleoside analogue 60 relapsed refractory 60 ISTODAX 60 Diffuse Large B 60 Symadex 60 molecularly targeted 60 invasive aspergillosis 60 velafermin 60 diagnosed multiple myeloma 60 belinostat 60 refractory Hodgkin lymphoma 60 Hormone Refractory Prostate Cancer 60 Philadelphia Chromosome Positive 60 predictive biomarkers 60 MEK inhibitor 60 ErbB2 positive 60 Multiple Myeloma MM 60 ALN TTR# 60 carboplatin paclitaxel 60 Gefitinib 60 plus dexamethasone 60 systemic lupus erythematosus 60 carcinoid tumors 60 HER2 positive cancers 60 LHRH analogues 60 localized renal 60 recurrent malignant glioma 60 Advaxis Phase 60 transthyretin amyloidosis 60 modified glutathione analog 60 alpha folate receptor 60 LHRH antagonist 60 refractory prostate cancer 60 papillary renal cell carcinoma 60 Vidofludimus 60 investigational pan BCR 60 PI3K inhibitor 60 paclitaxel Taxol 60 ENMD # 60 hepatoma 60 Alocrest 60 Solazed TM 60 IFN α 60 Sudhir Agrawal D.Phil 60 Glioblastoma Multiforme 60 evaluating T DM1 60 tumor recurrence 60 phenoxodiol 60 E#F# 60 investigational compound 60 hypoparathyroidism 60 CML CP 60 HCV genotype 1 60 cetuximab Erbitux 60 HSP# inhibitor 60 ISIS # 60 CCR5 tropic HIV 60 cangrelor 60 MEK inhibitors 60 advanced unresectable 60 Fludarabine 60 Bosutinib 60 Campath alemtuzumab 60 acute leukemias 60 huN# DM1 60 Safinamide 60 NEUVENGE 60 Laquinimod 60 LHRH agonist 60 TREANDA 60 imatinib mesylate Gleevec 60 Bevacizumab 60 tocilizumab 60 LHRH 60 compound ITMN 60 AQ4N 60 erlotinib 60 Lenocta 60 Her2/neu 60 CALGB # [001] 60 EVIZON 60 chemopreventive agent 60 #ME# 60 anticancer therapy 60 hormone LHRH agonist 60 xenograft models 60 Clolar ® 60 HuMax CD# 60 XYOTAX TM 60 bendamustine 60 cisplatin gemcitabine 60 HspE7 60 adalimumab Humira 60 KRAS mutations occur 60 omega interferon 60 tafamidis 59 Flu Cy 59 R roscovitine 59 colon carcinoma 59 mutated KRAS 59 refractory PTCL 59 investigational immunotherapy 59 renal carcinoma 59 small lymphocytic lymphoma 59 Vitaxin 59 trastuzumab 59 EGS# 59 vinca alkaloid 59 Tarvacin 59 metastatic 59 Triolex 59 KRN# 59 methylnaltrexone 59 CINTREDEKIN BESUDOTOX 59 glioblastoma 59 Familial Adenomatous Polyposis FAP 59 UPLYSO 59 T1DM 59 severe hypercholesterolemia 59 Randomized Phase 59 BCG refractory carcinoma 59 IRESSA 59 TNF α 59 HNSCC 59 QLT# 59 Castration Resistant Prostate Cancer 59 Prostate AdenoCarcinoma Treatment 59 essential thrombocythemia 59 Everolimus 59 epithelial ovarian cancer 59 prospectively defined 59 lymphocytosis 59 hypercalcemia 59 protein kinase inhibitor 59 FDG PET 59 INCB# [003] 59 CR nPR 59 Crohn disease CD 59 BCIRG 59 VEGF receptor inhibitor 59 essential thrombocythemia ET 59 unique alkylating agent 59 pharmacokinetic PK study 59 pT2 59 Eculizumab 59 rALLy 59 gemcitabine carboplatin 59 atrasentan 59 TELINTRA 59 TRAIL receptor 59 KRAS mutations 59 Myelodysplastic Syndrome 59 hyperplasia BPH 59 neratinib 59 Phase Ib clinical trials 59 EGFR HER2 59 FASLODEX 59 hypercholesterolemia 59 regorafenib 59 Janus kinase 59 Myelofibrosis 59 anti androgen 59 nilotinib Tasigna 59 HER-2/neu 59 immunomodulatory therapy 59 peritoneal carcinomatosis 59 myelodysplastic myeloproliferative diseases 59 Follicular Lymphoma 59 ospemifene 59 chemotherapeutic agent 59 Hsp# inhibition 59 grade cervical intraepithelial 59 PI3K Akt 59 interferon beta 1a 59 CCR5 antagonist 59 Panzem R 59 hA# 59 polymerase inhibitor 59 cintredekin besudotox 59 registrational 59 cisplatin chemotherapy 59 minimally symptomatic 59 AGTR1 59 Vectibix monotherapy 59 tumor xenograft models 59 DFMO 59 Sym# 59 biochemical recurrence 59 free survival PFS 59 SERMs 59 epothilone 59 T DM1 59 Phase #b/#a clinical 59 achieve sustained virologic 59 neoplasia 59 cisplatin resistant 59 Golimumab 59 subcutaneously administered 59 temozolomide 59 mTOR mammalian target 59 sustained virologic response 59 HGS ETR1 mapatumumab 59 bortezomib Velcade 59 Adjuvant chemotherapy 59 Diabetic Macular Edema 59 KRAS status 59 TACE 59 remission induction 59 randomized controlled Phase 59 neurogenic orthostatic hypotension 59 Response Evaluation Criteria 59 CCX# B 59 hypercholesterolemic patients 59 Seliciclib 59 MET amplification 59 Tavocept 59 TTF Therapy 59 cMET 59 plasma uric acid 59 haematological malignancies 59 APTIVUS r 59 eniluracil 59 non nucleoside HCV 59 urothelial carcinoma 59 alefacept 59 Randomized Phase II 59 BZL# 59 locoregional recurrence 59 PAOD 59 Cloretazine R VNP#M 59 Antitumor activity 59 KRAS oncogene 59 zalutumumab 59 RAV# 59 hyperuricemia 59 Tesetaxel 59 systemic lupus erythematosus SLE 59 MKC# MT 59 genotypic resistance 59 myelofibrosis MF 59 Factor Receptor 59 Phase III Pivotal 59 Solid Tumors 59 rituximab refractory 59 E1 INT TM 59 follicular lymphoma FL 59 indolent follicular non 59 relapsed AML 59 ribavirin therapy 59 TMC# C# 59 otelixizumab 59 lenalidomide dexamethasone 59 cytotoxic chemotherapy 59 chemoresistant 59 bicalutamide 59 tesmilifene 59 OvaRex R 59 JVRS 59 Fludara 59 docetaxel 59 previously untreated follicular 59 adjuvant chemotherapy 59 recurrent metastatic ovarian cancer 59 pegylated interferon alfa 2a 59 vorinostat 59 Pharmacokinetics PK 59 GRASPA ® 59 EDEMA4 59 Phase 2b clinical 59 imatinib resistance 59 CDK cyclin dependent 59 sorafenib 59 mycophenolate mofetil 59 LUX Lung 59 Teriflunomide 59 refractory ovarian cancer 59 TNF blocker therapy 59 rapid virologic response 59 p# mitogen activated 59 MAGE A3 59 dose escalation clinical 59 Archexin 59 CTA# Injection 59 stage IIIb 59 trastuzumab emtansine T DM1 59 MGUS 59 recurrent prostate cancer 59 DEB# 59 Tarceva TM 59 Mantle Cell Lymphoma 59 TBC# 59 NMIBC 59 nonmetastatic prostate cancer 59 BR.# 59 Natalizumab 59 Renal Cell Carcinoma RCC 59 Trofex 59 MEND CABG 59 hepatitis C HCV 59 Asentar 59 adefovir 59 kidney urologic 59 Ophena 59 MKC# MKC# PP 59 Taxotere ® 59 LE DT 59 Pirfenidone 59 flavopiridol 59 mycosis fungoides 59 recurrent ovarian 59 Heterozygous Familial Hypercholesterolemia 59 Metastatic Melanoma 59 Chemophase 59 ADAGIO study 59 Luteinizing Hormone Releasing Hormone 59 malignancies 59 relapsing remitting MS RRMS 59 HER2 antibody 59 adenocarcinomas 59 Elvitegravir 59 metastatic pancreatic 59 EGF receptor 59 Onconase 59 Carfilzomib 59 Perifosine 59 efaproxiral 59 ara C 59 DCVax R 59 pDCs 59 EFAPROXYN 59 metachronous